Schedules and protection, simultaneous vaccination and safety: Experiences from recent controlled trials

International Journal of Infectious Diseases

Volumn 1, Issue 3, 1997, Pages 143-147

  Olin, Patrick ^a   Rasmussen, Finn ^b   Gottfarb, Peter ^c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SACHS CHILDREN S HOSPITAL   (Sweden)

Author keywords

acellular; component; efficacy; pertussis vaccines; randomized controlled trial; reactogenicity; whole cell

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; ANOREXIA; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; MAJOR CLINICAL STUDY; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; VOMITING;

EID: 0030981777     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(97)90077-1     Document Type: Conference Paper

References (14)

1. Ad hoc group for the study of pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1988; 1:955-960. [Erratum, Lancet 1988; 1:1238]
2. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333:1045-1050.
3. Greco D, Salmaso S, Mastrantonio P, et al. Clinical efficacy, immunogenicity, and safety of two acellular and one whole-cell pertussis vaccines: results from the Italian Trial. N Engl J Med 1996; 334:341-348.
4. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
5. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccines: technical report, Trial I, with results of preplanned analysis of safety, efficacy, and immunogenicity. Stockholm, Sweden: Swedish Institute for Infectious Disease Control, 1995:20-70.
6. Halsey NA. New developments with pertussis vaccines. Pediatrics 1995; 96:970-971.
7. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:341-342.
8. Poland GA. Acellular pertussis vaccines: new vaccines for an old disease. Lancet 1996; 147:209-210.
9. WHO Meeting on Case Definition of Pertussis. Geneva, January 10-11, 1991. WHO Mim/Epi/Pert/91.1.
10. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus influenzae type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991; 10:758-761.
11. Fritzell B. Vaccin polyosidique contre Haemophilus influenzae b conjugué à la protéine tétanique. Tolérance et immunogénicité chez les nourrissons. Immunol Med 1991; 8:176-183.
12. A clinical trial of acellular pertussis vaccines in Sweden. Technical Report. Sweden: National Bacteriological Laboratory, 1988.
13. Edwards KM, Meade BM, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-557.
14. Global programme for vaccines and immunization. Immunization policy. Expanded programme on immunization. Geneva: World Health Organization, 1995.